ArticleCureus2025
A Prospective Observational Study Evaluating the Efficacy of Omalizumab and Mepolizumab in Patients With Severe Asthma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere asthma affects 5-10% of asthmatics and presents a significant challenge for healthcare systems despite therapeutic advances. Biologic therapies such as omalizumab and mepolizumab have emerged as promising treatments, but real-world comparative data remain limited.
objectiveTo evaluate and compare the efficacy and safety of omalizumab and mepolizumab in patients with severe asthma in a real-world clinical setting.
methodsThis prospective observational cohort study included 72 patients with severe asthma (40 receiving omalizumab and 32 receiving mepolizumab) at the respiratory clinic of Salmaniya Medical Complex, Bahrain. The primary outcome was asthma control as assessed by the Asthma Control Test (ACT). Secondary outcomes included lung function parameters (forced expiratory volume (FEV)1% predicted and FEV1/forced vital capacity (FVC) ratio), exacerbation rates, hospitalization rates, emergency room visits, quality of life, and safety (adverse events). Data regarding demographics, asthma history, treatment details, and patient-reported outcomes were collected over a 12-month follow-up period and analyzed.
resultsThe study revealed that 69.4% of all patients achieved well-controlled asthma, with the omalizumab group showing a significantly higher proportion of well-controlled patients (80.0%) compared to the mepolizumab group (56.3%, p=0.049). However, logistic regression analysis demonstrated that mepolizumab was associated with significantly higher odds of achieving high asthma control (adjusted OR: 8.95, 95% CI: 1.79-44.51, p=0.007) when controlling for other factors. Triple therapy (adjusted OR: 32.5, 95% CI: 12.85-53.11, p=0.030) and inhaled corticosteroid and long-acting beta-agonist (ICS-LABA) combination (adjusted OR: 17.43, 95% CI: 1.58-35.11, p=0.048) were strongly associated with improved asthma control. Quality of life was reported as excellent by 59.7% of patients, with a higher proportion in the omalizumab group (70.0%) compared to the mepolizumab group (46.9%).
conclusionBoth omalizumab and mepolizumab demonstrated effectiveness in managing severe asthma, with each showing distinct advantages in different outcome measures. Mepolizumab showed stronger independent associations with asthma control in multivariate analysis, while omalizumab-treated patients reported better quality of life. Treatment selection should be tailored to individual patient characteristics and therapeutic goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.